Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia^*

References

• Madisch A, Miehlke S, Labenz J. Management of functional dyspepsia: Unsolved problems and new perspectives. World J Gastroenterol 2005; 11:6577–81
   PubMed Web of Science ®Google Scholar
• Baker G, Fraser RJ, Young G. Subtypes of functional dyspepsia. World J Gastroenterol 2006; 12:2667–71
   PubMed Web of Science ®Google Scholar
• Shaib Y, El-Serag HB. The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States. Am J Gastroenterol 2004; 99:2210–6
   PubMed Web of Science ®Google Scholar
• Tougas G, Chen Y, Hwang P, . Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. Am J Gastroenterol 1999; 94:2845–54
   PubMed Web of Science ®Google Scholar
• Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther 2006; 24:475–92
   PubMed Web of Science ®Google Scholar
• Talley NJ. Non-ulcer dyspepsia: myths and realities. Aliment Pharmacol Ther 1991; 5 (Suppl 1) 145–62
   PubMed Web of Science ®Google Scholar
• Talley NJ, Colin-Jones D, Koch M, . Functional dyspepsia; a classification with guidelines for diagnosis and management. Gastroenterology International 1991; 4:145–60
   Google Scholar
• Talley NJ, Stanghellini V, Heading RC, . Functional gastroduodenal disorders. Gut 1999; 45 (Suppl 2) II37–42
   PubMedGoogle Scholar
• Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006; 15:237–41
   PubMedGoogle Scholar
• Talley NJ. Therapeutic options in nonulcer dyspepsia. J Clin Gastroenterol 2001; 32:286–93
   PubMed Web of Science ®Google Scholar
• de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter 2007; 12:1–15
   PubMed Web of Science ®Google Scholar
• Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies. Gut 2002; 50 (Suppl 4) iv36–41
   PubMedGoogle Scholar
• Moayyedi P, Soo S, Deeks J, . Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; 1:CD002096
   PubMedGoogle Scholar
• Talley NJ. Dyspepsia: management guidelines for the millennium. Gut 2002; 50 (Suppl 4) iv72–8
   PubMedGoogle Scholar
• Talley NJ. Review article: dyspepsia: how to manage and how to treat? Aliment Pharmacol Ther 2002; 16 (Suppl 4) 95–104
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Delaney BC, Vakil N, . The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127:1329–37
   PubMed Web of Science ®Google Scholar
• Bolling-Sternevald E, Lauritsen K, Aalykke C, . Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002; 37:1395–402
   PubMed Web of Science ®Google Scholar
• Peura DA, Gudmundson J, Siepman N, . Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 2007; 52:983–7
   PubMed Web of Science ®Google Scholar
• Mounsey AL. Lansoprazole ineffective for functional dyspepsia. J Fam Pract 2002; 51:1015
   PubMedGoogle Scholar
• Nyren O. Functional dyspepsia: bye-bye to PPIs. Gut 2002; 51:464–5
   PubMed Web of Science ®Google Scholar
• van Zanten SV, Armstrong D, Chiba N, . Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled ‘ENTER’ trial. Am J Gastroenterol 2006; 101:2096–106
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Soo S, Deeks J, . Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006. 2. CD002096
   Google Scholar
• Cheer SM, Prakash A, Faulds D, . Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63:101–33
   PubMed Web of Science ®Google Scholar
• Blume H, Donath F, Warnke A, . Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety 2006; 29:769–84
   PubMed Web of Science ®Google Scholar
• Manning AP, Thompson WG, Heaton KW, . Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2:653–4
   PubMed Web of Science ®Google Scholar
• Svedlund J, Sjödin I, Dotevall G. GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33:129–34
   PubMed Web of Science ®Google Scholar
• Dimenäs E, Glise H, Hallerbäck B, . Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28:681–7
   PubMed Web of Science ®Google Scholar
• Stanghellini V, Armstrong D, Monnikes H, . Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004; 19:463–79
   PubMed Web of Science ®Google Scholar
• Talley NJ, Locke GR, Lahr BD, . Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 2006; 23:923–36
   PubMed Web of Science ®Google Scholar
• Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005; 17:325–31
   PubMed Web of Science ®Google Scholar
• Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 2006; 41:513–23
   PubMed Web of Science ®Google Scholar
• Tack J, Talley NJ, Camilleri M, . Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466–79
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Soo S, Deeks J, . Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006. 4: CD001960
   Google Scholar
• Wong WM, Wong BC, Hung WK, . Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51:502–6
   PubMed Web of Science ®Google Scholar
• Blum AL, Arnold R, Stolte M, . Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut 2000; 47:473–80
   PubMed Web of Science ®Google Scholar
• Peura DA, Kovacs TO, Metz DC, . Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004; 116:740–8
   PubMed Web of Science ®Google Scholar
• Talley NJ, Meineche-Schmidt V, Pare P, . Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12:1055–65
   PubMed Web of Science ®Google Scholar
• Wallander MA, Johansson S, Ruigómez A, . Unspecified abdominal pain in primary care: the role of gastrointestinal morbidity. Int J Clin Pract 2007; 61:1663–70
   PubMed Web of Science ®Google Scholar
• Wallander MA, Johansson S, Ruigómez A, . Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Fam Pract 2007; 24:403–11
   PubMed Web of Science ®Google Scholar
• Meineche-Schmidt V. Empiric treatment with high and standard dose of omeprazole in general practice: two-week randomized placebo-controlled trial and 12-month follow-up of health-care consumption. Am J Gastroenterol 2004; 99:1050–8
   PubMed Web of Science ®Google Scholar
• Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, . A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005; 100:1477–88
   PubMed Web of Science ®Google Scholar
• Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11:541–6
   PubMed Web of Science ®Google Scholar
• Heikkinen M, Farkkila M. What is the long-term outcome of the different subgroups of functional dyspepsia? Aliment Pharmacol Ther 2003; 18:223–9
   PubMed Web of Science ®Google Scholar
• Talley NJ. Functional gastrointestinal disorders in 2007 and Rome III: something new, something borrowed, something objective. Rev Gastroenterol Disord 2007; 7:97–105
   PubMed Web of Science ®Google Scholar
• Blum AL, Talley NJ, O'Morain C, . Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998; 339:1875–81
   PubMed Web of Science ®Google Scholar
• Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ 1999; 319:1040–4
   PubMed Web of Science ®Google Scholar
• McColl K, Murray L, El-Omar E, . Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339:1869–74
   PubMed Web of Science ®Google Scholar
• Hojo M, Miwa H, Yokoyama T, . Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005; 40:1036–42
   PubMed Web of Science ®Google Scholar
• Van Rensburg CJ, Enns R, Dattani I, . Pantoprazole 20 mg o.d. is superior to placebo in the treatment of epigastric pain in patients with ulcer-like functional dyspepsia. Results of a multinational study. Gastroenterology 2002; 122 (Suppl I) T1524
   Google Scholar
• Van Rensburg CJ, Enns R, Dattani I, . Pantoprazole (Pz) 20 mg o.d. is superior to placebo in the treatment of epigastric pain (EP) in patients with ulcer-like functional dyspepsia (ULFD). Results of a multinational study. S Afr Med J 2002; 92:572
   PubMed Web of Science ®Google Scholar